Abstract 400P
Background
Long non-coding RNAs (LncRNAs) play a critical part in tumor growth and metastasis, but only a small number of LncRNAs are functionally annotated.
Methods
The GEO database was used to analyze breast cancer-related transcriptome data and identify the differentially expressed LncRNA-LINC00294, and qRT-PCR was used to validate the expression of LINC00294 in 30 pairs of breast and para cancer tissues, as well as normal human breast epithelial cells MCF-10A and breast cancer cells MDA-MB-231, SK-BR-3, and MCF-7. The influence of LINC00294 overexpression/interference on the biological properties of breast cancer cells was validated using Western Blot, Transwell, scratch assay, flow cytometry, and CCK-8; the infection of LINC00294 overexpression on the growth of breast tumors in vivo was validated using an in situ tumorigenesis assay in nude mice; the effects of LINC00294 overexpression on the growth of breast tumors in vivo were inquired using Western Blot. The infection of LINC00294 in breast cancer cell biology was investigated by Western Blot, Transwell, scratch assay, and luciferase reporter to investigate the mechanism by which LINC00294 affects breast cancer development via ceRNA adsorption and thus regulates JUP expression.
Results
LINC00294 was significantly upregulated in breast cancer tissues. Furthermore, interference with LINC00294 significantly inhibited breast cancer cell multiplication, invasion, and migration, while overexpression of LINC00294 promoted breast cancer cell invasion proliferation, proliferation, and migration, as well as tumor growth. According to mechanistic studies, LINC00294 could regulate JUP expression and thus the Wnt/β-catenin signaling pathway by targeting miR-485-5p, thus affecting the development of breast cancer.
Conclusions
LINC00294 is highly expressed in breast cancer and may spaciously adsorb miR-485-5p through the ceRNA mechanism to regulate JUP expression, which in turn regulates the Wnt/β-catenin signaling pathway and affects the development of breast cancer. Our findings show that LINC00294 has an effect on breast cancer and identifies a new possible prognostic marker and therapeutic target for this disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
the 'Kuanren meritocrat'Backbone Talents Project of The Second Affiliated Hospital of Chongqing Medical University (no. KY2019G016), Wu Jiping Medical Foundation (no.320.6750.2021-10-86) and Natural Science Foundation of Chongqing, China(no.CSTB2022NSCQ-MSX0055).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
393P - A phase II study to evaluate the efficacy and safety of TSL-1502 capsules in breast cancer patients with germline BRCA mutations
Presenter: Bo Lan
Session: Poster session 15
394P - Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC)
Presenter: Paolo Tarantino
Session: Poster session 15
395P - Receptor status heterogeneity during metastatic breast cancer treatment
Presenter: Sandra Geurts
Session: Poster session 15
396P - Evaluation of MUC1-C/CD3 biparatopic-bispecific (BPBS) T cell engager as an immunotherapeutic agent for the treatment of MUC1-expressing metastatic breast cancer (mBC)
Presenter: Ravi Jasuja
Session: Poster session 15
397P - Survival of de novo metastatic breast cancer according to biomarker status in Denmark and Norway: A register-based cohort study
Presenter: Johan Liseth Hansen
Session: Poster session 15
398P - Age and ethnic-driven molecular and clinical disparity of East Asian breast cancers
Presenter: Ji Yoon Lee
Session: Poster session 15
399P - Treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States
Presenter: Shanu Modi
Session: Poster session 15
401P - Evaluation of HER2 scoring in breast carcinoma-stained whole slide images
Presenter: Céline Bossard
Session: Poster session 15
402P - Inflammatory biomarkers for predicting the efficacy of immunotherapy in advanced breast cancer
Presenter: Kuikui Jiang
Session: Poster session 15
403P - Stemness-targeted therapies to inhibit cancer cell plasticity in triple negative breast cancer
Presenter: Andrew Takchi
Session: Poster session 15